Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 21, 2022 03:30 ET | Source: Nexstim Oyj

Meddelande om Nexstim Abp 2021 helårsresultat

Företagsmeddelande, Helsingfors, 21 februari 2022 kl 10.30 (EET) Meddelande om Nexstim Abp 2021 helårsresultat Nexstim Abp (NXTMH:HEX, NXTMS:STO) (”Nexstim” eller ”bolaget”) kommer att meddela sitt...
February 16, 2022 02:30 ET | Source: Nexstim Oyj

Nexstim Receives a System Upgrade Order from a Customer in Finland

Press release, Helsinki, 16 February 2022 at 9:30 AM (EET) Nexstim Receives a System Upgrade Order from a Customer in Finland Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") has received...
February 14, 2022 02:00 ET | Source: Nexstim Oyj

Nexstim Plc to license technology to US-based medical technology company Magnus Medical, Inc. for the treatment of neuropsychiatric disorders

Company Announcement, Inside Information, Helsinki, 14 February 2022, at 9 AM (EET) Nexstim Plc to license technology to US-based medical technology company Magnus Medical, Inc. for the treatment of...
February 14, 2022 02:00 ET | Source: Nexstim Oyj

Nexstim Oyj lisensoi kehittämäänsä teknologiaa yhdysvaltalaiselle lääkintäteknologiayhtiö Magnus Medical, Inc.:ille käytettäväksi neuropsykiatrisien häiriöiden hoitoon

Yhtiötiedote, sisäpiiritieto, Helsinki, 14.2.2022 klo 9.00 (EET) Nexstim Oyj lisensoi kehittämäänsä teknologiaa yhdysvaltalaiselle lääkintäteknologiayhtiö Magnus Medical, Inc.:ille käytettäväksi...
February 14, 2022 02:00 ET | Source: Nexstim Oyj

Nexstim Abp licensierar ut teknik till det amerikanska medicinteknikföretaget Magnus Medical, Inc. för behandling av neuropsykiatriska tillstånd

Företagsmeddelande, insiderinformation, Helsingfors 14.2.2022 kl. 9.00 (EET) Nexstim Abp licensierar ut teknik till det amerikanska medicinteknikföretaget Magnus Medical, Inc. för behandling av...
February 03, 2022 08:15 ET | Source: Nexstim Oyj

Nexstim Reaches Over 300 Completed Treatment Sessions – Continues to Report a Remission Rate Greater than 50% of MDD Patients in the Patient Registry

Press release, Helsinki, 3 February 2022 at 3:15 PM (EET) Nexstim Reaches Over 300 Completed Treatment Sessions – Continues to Report a Remission Rate Greater than 50% of MDD Patients in the Patient...
January 24, 2022 02:00 ET | Source: Nexstim Oyj

Nexstim Receives an NBS 5+ System Order from a Customer in the US

Press release, Helsinki, 24 January 2022 at 9 AM (EET) Nexstim Receives an NBS 5+ System Order from a Customer in the US Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces having...
January 03, 2022 05:30 ET | Source: Nexstim Oyj

Nexstim Has Closed the Strategic Investment into a Management Services Organisation of a California Based Clinic Providing Treatments for Depression Patient

Company Announcement, Helsinki, January 3, 2022 at 12:30 PM (EET) Nexstim Has Closed the Strategic Investment into a Management Services Organisation of a California Based Clinic Providing Treatments...
January 03, 2022 05:30 ET | Source: Nexstim Oyj

Nexstim on saattanut loppuun järjestelyn strategisesta investoinnista masennuspotilaille hoitoja tarjoavaan kalifornialaisen klinikan palveluyhtiöön

Yhtiötiedote, Helsinki, 3.1.2022, klo. 12.30 (EET) Nexstim on saattanut loppuun järjestelyn strategisesta investoinnista masennuspotilaille hoitoja tarjoavaan kalifornialaisen klinikan palveluyhtiöön...
January 03, 2022 05:30 ET | Source: Nexstim Oyj

Nexstim har avslutat transaktionen angående en strategisk investering i en Management Services-organisation för en Kalifornien-baserad klinik som tillhandahåller behandlingar för depressionspatienter

Företagsmeddelande, Helsingfors, 3.1.2022 kl 12.30 (EET) Nexstim har avslutat transaktionen angående en strategisk investering i en Management Services-organisation för en Kalifornien-baserad klinik...